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Summary
Ultrasound (US) has become a useful tool in the detection
of early disease, differential diagnosis, guidance of treat-
ment decisions and treatment monitoring of rheumatoid
arthritis (RA). In 2008, the Swiss Sonography in Arthritis
and Rheumatism (SONAR) group was established to pro-
mote the use of US in inflammatory arthritis in clinical
practice. A scoring system was developed and taught to a
large number of Swiss rheumatologists who already con-
tributed to the Swiss Clinical Quality Management
(SCQM) database, a national patient register. This paper in-
tends to give a Swiss consensus about best clinical prac-
tice recommendations for the use of US in RA on the basis
of the current literature knowledge and experience with the
Swiss SONAR score.
Literature research was performed to collect data on cur-
rent evidence. The results were discussed among specialists
of the Swiss university centres and private practice, follow-
ing a structured procedure.
Musculoskelatal US was found to be very helpful in estab-
lishing the diagnosis and monitoring the evolution of RA,
and to be a reliable tool if used by experienced examin-
ers. It influences treatment decisions such as continuing,
intensifying or stepping down therapy. The definite mod-
alities of integrating US into the diagnosis and monitoring
of RA treatments will be defined within a few years. There
are, however, strong arguments to use US findings as of
today in daily clinical care. Some practical recommenda-
tions about the use of US in RA, focusing on the diagnosis
and the use of the SONAR score, are proposed.
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Introduction
The diagnosis of rheumatoid arthritis (RA) is based essen-
tially on clinical and biological parameters, although the
new ACR/EULAR classification criteria include magnetic
resonance imaging (MRI) and ultrasound (US) as addition-
al tools to assess objectively joint involvement [1, 2].
The primary treatment goal in RA is to maximise long-term
health-related quality of life by controlling the symptoms,
preventing structural damage, normalising or preserving
function, and enhancing social participation. Since the era
of the new biologic treatments, these goals can be achieved
in most patients and the benefit of tight disease control has
been demonstrated. To optimise outcome, therapies should
be adjusted according to disease activity. The ACR (Amer-
ican College of Rheumatism) response criteria were not es-
tablished for clinical practice but rather for clinical trials.
In contrast, the DAS (disease activity score), CDAI (clinic-
al disease activity index) and SDAI (simplify disease activ-
ity index) are clinically useful for the continuous prospect-
ive monitoring of individual patients [3] . In many studies,
however, these indexes, in particular the DAS, yielded a
low reproducibility when applied in the setting of a large
group of physicians [4]. Up to 30% of patients fulfilling
remission criteria according to DAS, ACR and European
League against rheumatism (EULAR) criteria still had pro-
gression in joint damage, suggesting that clinical criteria
may not be reliable [5].
There are more and more data suggesting that US is useful
in differential diagnosis, detection of early disease, disease
activity monitoring, guidance of treatment decisions, and
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in the follow-up of remission of RA [6]. Over the last dec-
ade, US technology and machines have progressed such
that good quality machines are now available for a reason-
able price, allowing a wide distribution among rheumato-
logists in both clinical and private practice. In Switzerland,
about 40% of rheumatologists have access to an US ma-
chine and have received basic training in musculoskeletal
US. Moreover, US has been included in the formal training
curriculum for all future Swiss rheumotologists.
In 2008, the Swiss Sonography in Arthritis and Rheum-
atism (SONAR) group was set up as an educational pro-
gamme focussing on the use of US in inflammatory arth-
ritis in clinical practice. A semiquantitative grayscale (B)
mode and doppler (PD) score was developed in accordance
with several earlier published scores and based on the re-
commendations of the of the OMERACT [7]. The scoring
system was taught to 108 rheumatologists.
This paper summarises a Swiss consensus on best clinical
practice recommendations for the use of US in RA, based
on the current literature and experience with the Swiss
SONAR score since it was implemented in the Swiss RA
registry database (SCQM).
The literature research, including the SONAR score data,
was discussed by a panel of experts from leading Swiss
rheumatology departments, researchers and clinicians, as
well as members of the international Targeting US Initi-
ative (TUI), and board certified rheumatologists in private
practice with extensive training in US.
Ultrasound and joint inflammation
Synovitis can be demonstrated by US, appearing as hypo-
echogenic hypertrophy of synovial tissue in greyscale (B-
mode). With the new US machines, synovial hypertrophy
can be distinguished from fluid collection in most cases.
For the detection of synovial hypertrophy, US is much
more sensitive than clinical examination and can compare
to MRI, especially when finger joints are evaluated [8].
The presence of vascularisation inside the synovial tissue
in Doppler (PD) mode reflects active inflammation [9].
However the performance of PD is highly dependent on the
quality of the machine, as well as subtle modification of the
settings, the experience of the operator and the localisation
of the examined joint (best in superficial joints) [10–11].
US can also differentiate between synovial inflammation
and tenosynovitis, bursitis and other soft tissue lesions that
can mimic clinical synovitis [7–8].
US can detect erosions at an earlier stage than traditional
X-rays, especially in finger joints. Erosion scoring is,
however, very time-consuming and can be difficult to per-
form in some joints [2].
Finally, cartilage lesions (loss of thickness, crystal depos-
its) can be assessed by this modality, especially in the small
joints of the hands that are frequently involved in RA [12].
Ultrasound in the detection of early
rheumatoid arthritis and in the
differential diagnosis of synovitis
A pivotal element in the diagnosis of RA is the presence
of synovitis in index joints. Joint involvement refers to any
swollen or tender joint on examination, which may be con-
firmed by evidence of synovitis on imaging [13]. Several
studies confirmed that US is a valid tool and is more sens-
itive than clinical examination in the detection of synovitis
[8]. Hence, adding US to a clinical prediction rule (Leiden
rule) in early RA raises the predictability of RA diagnosis
[14].
However, some precautions must be considered before us-
ing US systematically for the diagnosis of early RA. Only
a very limited number of studies have, to our knowledge,
evaluated the performance and the prognostic relevance of
the new ACR/EULAR criteria with and without the use of
US [15]. Moreover, significant US synovitis has not been
clearly defined by the ACR/EULAR committee, and some
studies have shown that US synovial hypertrophy can also
be found in osteoarthritis and even in controls without any
joint disease [16].
Some US signs can help to distinguish RA from other
causes of arthritis. For example in early psoriatic arthritis
(PsA), hypoechoic swelling surrounding the extensor di-
gitorum tendon and peritendinous PD signal seem to pre-
dominate compared with intra-articular PD signal in early
RA [17]. The described US pattern in PsA seems to con-
firm the presence of enthesitis [17–18]. US findings such
as the presence of a hyperechoic signal within the cartilage
layer (calcium pyrophosphate [CPPD] deposition disease)
[19] or very superficial cartilage crystals (“double contour”
sign in gout) [20] have been described (fig. 1). For CPPD
crystal deposition, US imaging can give a positive likeli-
hood ratio (LR) as high as 7.9–29, compared with a much
lower positive LR for synovial fluid analysis (7.0) and
plain radiography (0.36) [21–22]. Therefore, US has been
proposed as an important method for the early diagnosis of
CPPD crystal deposition [23]. There are, however, no con-
trolled studies that have examined the capability of US to
distinguish morphologically early RA from crystal-associ-
ated joint diseases. Osteophytes, one of the morphologic-
al hallmarks of osteoarthritis, can also reliably be assessed
by US with a good agreement between MRI and US. Of
note, US is more sensitive than conventional radiology and
clinical examination [2, 4–25]. All of the above-mentioned
Figure 1
"Double contour" sign in gouty arthritis (white arrows): dorsal view
of several metatarso-phalangeal joints performed outside an acute
flare of gout.
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findings support the idea that US may add important in-
formation to the differential diagnosis of articular diseases
[26].
In clinical studies, the reliability of US repeatedly has been
shown to be superior to the clinical evaluation for the dif-
ferentiation between arthritis and arthralgia [8]. A normal
US with nonspecific arthralgia could, therefore, help to dif-
ferentiate arthritis from fibromyalgia or other nonspecific
painful conditions. However, more studies are needed to
evaluate the exact role of US in the diagnosis of inflammat-
ory arthralgia and undifferentiated inflammatory arthritis.
Ultrasound scores for rheumatoid
arthritis
US can be used to demonstrate the presence of synovitis in
individual joints. RA is a polyarticular disease and, there-
fore, US has essentially been studied as a tool for diagnosis
and follow-up by scoring many joints. How many and
which joints should be included, which view of the joints
to be examined (volar or palmar), the quantification of
synovitis (yes/no, semiquantitative), which mode (B-mode
only, separated from Doppler or combined) are still de-
bated. At this stage, there is no commonly accepted stand-
ardised score, although the OMERACT has proposed min-
imal criteria for validation [26].
Several different scores for US have been studied and val-
idated. The first ones comprised up to 68 joints. To render
them more feasible for daily practice, investigators have
progressively reduced the number of examined joints. The
validated Spanish score examines 12 joints including the
feet. It comprises B-mode and PD-mode with a semi-quant-
itative score according to the OMERACT recommenda-
tions [27]. In the hands and the feet, B-mode is performed
by examining the dorsal side of the joints. The Berlin score
examines seven joints, including hands and feet with a pal-
mar view in the hands for B-mode [28].
Figure 2
Synovitis grade 1-3 on B mode: proximal inter-phalangeal joint.
RA and other forms of inflammatory polyarthritis like
psoriatic arthritis can also involve tendons and bursae.
Several attempts to develop scoring systems limited to ten-
osynovitis or including tenosynovitis in a synovitis score
have been proposed [29]. Some have been validated like
the German seven-joint score, which includes also tenosyn-
ovitis of the wrist and fingers [28], but their prognostic sig-
nificance has not yet been fully evaluated.
The Swiss SONAR score analyses 22 joints in order to
include approximately the same joints as the DAS, but
excluding the thumbs and shoulders. These joints were
excluded because they could be the site of common rheum-
atological problems not related to RA (osteoarthritis, rotat-
or cuff lesions and other disorders). The score includes the
palmar view of joints for B-mode, with a semiquantitative
assessment in accordance with the Berlin score (fig. 2) and
the dorsal view in PD-mode (fig. 3). The scanning time is
between 10 and 15 minutes including PD evaluation. The
cartilage thickness and presence of bony erosions and ten-
osynovitis can be assessed optionally.
Validation of the scores
Although the criteria of validation varied from one pub-
lication to the other, they usually included reproducibility
(inter- and intra-operator with or without image acquisi-
tion) [30–32], correlation with the clinical scores (DAS,
CDAI, etc.) [30–31] and responsiveness to treatments, usu-
Figure 3
Synovitis grade 1-3, PD activity: dorsal view of a metacarpo-
phalangeal joint. Presence of an erosion.
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ally assessed by measurement of standardised response
mean (SRM) [30–31]. The Spanish and Berlin scores, were
validated in selected patients by a limited number of well-
trained and experienced US specialists with high-quality
machines and after training as well as strict standardisation
[27–28].
For the SONAR score, the inter-reader reproducibility was
studied among a subset of 12 rheumatologists who had at-
tended our teaching module 1 year before the validation
procedure [33]. The reproducibility was fairly good (kappa:
0.53 for B-mode – 0.85 for Doppler) when the ultrasono-
grapher had had some practical experience since the teach-
ing (at least five patients with a SONAR score included in
the SCQM). We used the data in the SCQM registry from
2009 onwards, where 980 US examinations (including 40
controls without rheumatic diseases) had been scored by
different operators in real-life conditions in order to valid-
ate the correlation between the DAS and responsiveness to
therapy by SRM measurements. The mean Pearson correla-
tion coefficient, r (0.40 for B-mode – 0.41 for Doppler) and
the mean SRM (0.80 for B-mode ‒ 0.86 for Doppler) were
in the same ranges as those obtained in controlled studies
[34].
Validation of the score under these conditions confirms
the feasibility and possible integration of an US scoring
system for RA monitoring into daily clinical practice. We
must however emphasise that the SONAR, like most other
scores, has been developed for the follow-up of RA pa-
tients and not for diagnosis or to differentiate RA from oth-
er types of inflammatory arthritis. No study evaluating the
SONAR score for these topics has yet been done. It can.
However. differentiate well controls without any musculo-
skeletal symptoms from RA patients, even when in remis-
sion [35].
Ultrasound in established rheumatoid
arthritis
US has been intensively studied in established RA. Dif-
ferent aspects have been evaluated: the correlation of US
scores with other validated methods of measuring disease
activity, such as the DAS; the ability of US to predict pro-
gression of structural damage such as erosions; the use of
US as a single or a complementary outcome measure in a
“treat-to-target” strategy; and, finally, the role of US ima-
ging in defining remission.
Correlation of ultrasound scores with other methods
for the assessment of disease activity
Whichever score is studied, there is a significant correla-
tion between US scoring and classical categories of DAS
activities: remission (<2.6), low disease activity (≥2.6 to
<3.2), moderately active disease (≥3.2 to <5), very active
disease (≥5.1). On an individual level there are, however,
many discordances. These discrepancies may have several
explanations. The lack of reproducibility of the DAS, es-
pecially when performed by many different rheumatolo-
gists, is a well-known problem [4]. Another reason might
be some heterogeneity in the quality of US examinations
when performed by many different operators, as was the
case in the SONAR score validation study. However, DAS
measurements have been shown to be even more hetero-
geneous than US scorings [29]. Therefore, we think that US
could be more reliable for the assessment of disease activ-
ity in routine practice than the classical clinical scores.
Individual discordances may also reflect real differences
because clinical and US examinations provide comple-
mentary information on the arthritis status. Moreover, it
seems that B- and Doppler-mode must be interpreted separ-
ately. The level of greyscale synovitis correlates better with
disease duration, and probably reflects the level of previous
inflammation and some fibrotic change, whereas the pres-
ence of PD signal seems less dependent on disease dura-
tion, but could be a better marker of ongoing inflammation
[36].
Ultrasound and “treat-to-target” strategy
Treating RA patients in accordance with clinical targets has
been shown to improve outcome [37]. In randomised con-
trolled studies, the ACR criteria response core dataset was
the gold standard for assessing disease activity. In recent
years, other scores such as the DAS, SDAI or CDAI have
also been introduced and are increasingly applied in stud-
ies, as well as in practice.
A few studies have suggested that the addition of an US
assessment to the management of patients with inflam-
matory arthritis improves the prediction of clinical out-
comes [38]. Treatment in accordance with imaging meas-
ures could therefore provide better outcomes than treat-
ment in accordance with clinical targets alone. This state-
ment has not yet been fully confirmed and is under invest-
igation in three prospective randomised multicentre stud-
ies. The use of US imaging to tailor the intensity of therapy
should also be validated in registry cohorts such as the
SCQM before its widespread use in routine practice is def-
initely recommended.
Ultrasound and prediction and assessment of joint
damage
The detection of structural damage is of major prognostic
importance and may determine future treatment decisions.
In most randomised studies, erosion status before and after
treatment has been assessed by standard X-rays with the
application of validated scores, in particular the Sharp/van
der Heijde or the Genant scores. In the early stages of
the disease, computed tomography (CT) might be the gold
standard for detection of the first erosions. Disadvantages
of CT are radiation hazard, availability issues and costs.
With MRI, very small erosions can be detected, and bone
marrow oedema visualised with MRI even predicts the oc-
currence of erosions. On the other hand, several publica-
tions have confirmed that US performs almost as well as
MRI and CT [39–40] for the detection of erosions. Ac-
cording to one randomised trial, PD US is an excellent
predictor of subsequent joint damage in the affected joint
[41]. However, although US is an excellent method to de-
tect small and first erosions at accessible joints, such as the
metacarpo-phalangeal, the proximal interphalangeal and
the metatarsophalangeal joints, its value is more limited at
sites such as the carpal or the midfoot joints. In follow-
up it may be very difficult to compare erosive status as-
sessed with US. Moreover, only a few controlled studies
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have compared US and regular X-rays for the prediction of
long-term joint damage [42, 43].
Thus, the use of US for the detection of erosions in routine
practice needs to be further evaluated. Indeed, there is, to
our knowledge, no registry study in which the detection of
erosions by US has been analysed. Although the SONAR
score includes the assessment of bony erosions, comparis-
on with plain X-rays has not been performed yet.
Ultrasound evaluation of disease remission
The main treatment goal in RA is to achieve a state of dis-
ease remission. However, no consensus exists on what con-
stitutes clinical remission. A few remission criteria have
been developed, in particular by the ACR and EULAR
groups [43]. A DAS28 score of less than 2.6 is the most
commonly used definition of remission because it can be
easily applied in randomised clinical trials and in routine
practice. The SDAI and the CDAI are less complex com-
posite indices that have been derived from the DAS. They
may more accurately reflect a state of disease remission
than DAS28 remission scores [45]. These scores are not
calculated in the SCQM registry and, therefore, are not
used by most Swiss rheumatologists. In addition, many
studies indicate that the DAS as well as the SDAI and
CDAI remission definitions [2] reflect a measure of minim-
al RA disease activity rather than a true remission. Indeed,
up to 30% of patients in remission show progression of
erosions and joint damage on radiographs [46–47], and
stopping the medication rapidly leads to flares in most of
them [47].
In 2011, the ACR/EULAR committee proposed new, more
stringent criteria for the definition of remission that could
better predict the absence of structural damage progression
[1]. The ACR/EULAR Boolean criteria include tender joint
count of ≤1, swollen joint count of ≤1, serum C-reactive
protein levels of ≤10 mg/l, and a patient global assessment
of ≤10/100 mm on a visual analogue scale or a SDAI score
of ≤3.3. The pertinence of this very strict remission defin-
ition has not yet been fully evaluated, in particular for the
decision of stopping or tapering treatments, prediction of
flares or absence of progression of erosions [1].
Six controlled trials have studied the use of US to define
remission [38]. Concordant preliminary conclusions can be
drawn [8], although four of the studies were performed by
the same group, the number of joints scanned varied from
one study to the other as did the definition of clinical and
US remission . A significant number of patients fulfilling
the clinical remission definitions still present US synovit-
is [2, 49–52]. This was recently confirmed in daily routine
care by a study performed in patients included in the Swiss
SCQM registry and using the SONAR score. More than
one-third of all RA patients in clinical remission accord-
ing to either the DAS28 definition (140 patients) or ACR/
EULAR criteria (40 patients) showed persistence of US
synovitis [35].
In patients considered to be in remission, two studies have
evaluated whether US could better predict progression and
flares after treatment discontinuation than the clinical
scores [50–52]. The persistence of PD activity was the best
predictor of subsequent radiological damage and flares in
both studies [52–54].
In the absence of a consensus about a US scoring system,
a unique definition of US remission cannot be proposed,
each scoring system having its own definition and valida-
tion. However, it seems that the absence of synovitis ac-
cording to PD activity should be considered as the main cri-
terion of remission [54].
Practical aspects
In our literature review, we have not done a systematic ana-
lysis that could allow us to classify our recommendations
according to precise levels of evidence. In fact, there is, to
our knowledge, as yet no peer review on these topics that
has proposed international recommendations based on a
class- and evidence-grading system. Therefore, the follow-
ing practical recommendations for the use of US in clinical
practice are based not only on literature data, but also on
a critical review of our experience with the SONAR score
by a panel of experts from leading Swiss rheumatology
centres. They will be useful mostly for the Swiss rheumato-
logists who already are or intend to use US scoring for RA
patients.
Recommended scoring system
In the absence of a unique US scoring system recognised
by the ACR or EULAR committees, we recommend that
Swiss rheumatologists use the SONAR score. More than
100 rheumatologists have been trained in the application of
this score and the score has been validated. Correlation of
the SONAR score with disease activity scores, including
remission and sensitivity to changes in disease activity, is
similar to other published scores. Moreover, the SONAR
score is unique because of its inclusion in a national re-
gistry database (SCQM). This allows assessment of not
only the management of the clinical disease but also the ap-
plication of US in RA. Results can be very easily documen-
ted online during the examination. The results are directly
reported to the summary table where they can be compared
with clinical assessments, in particular with the DAS28
score and the patient questionnaires. The combination of
clinical composite scores with imaging data (X-Ray and
US) is particularly useful for treatment monitoring in daily
practice. The US score application in the SCQM database
will be adapted according to future research data and the
future development of a validated international score.
Recommended indications
Diagnosis
a) Patients with polyarthralgia and absence of overt
signs of clinical synovitis
US is a useful tool in addition to clinical, biological and
conventional radiographic data to establish the presence of
arthritis. Some specific imaging patterns identified by US
examination can help to clarify the differential diagnos-
is. The use of US examinations as a diagnostic procedure
should not be limited to the SONAR score but must, for
instance, include the assessment of additional joints or the
presence of enthesites.
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b) Patients with suspected rheumatoid arthritis but
insufficient criteria for the diagnosis
The new 2010 ACR/EULAR classification criteria can
serve as a reasonable basis for the diagnosis of RA, es-
pecially at an early stage. It implies at least one clinically
swollen joint. As the number of affected joints increases
the probability of RA diagnosis, US can be used to identify
the number of swollen joints. However, no clear definition
of US synovitis was provided in the article including the
RA classification criteria [2]. According to our experience,
only grade 2 on B-mode without or with PD activity should
be considered as significant for the presence of synovitis
[4]. Of note, the SONAR score does not take into account
the presence of synovitis in the feet and hips or shoulders.
As the 2010 ACR/EULAR classification criteria of RA
also includes these joints, the search for synovitis with US
should not be restricted to the SONAR score.
c) Follow-up of patients with established rheumatoid
arthritis
When RA is recently diagnosed, we recommend a baseline
SONAR score in addition to baseline standard X-rays, and
the use of at least one of the following clinical activity in-
dices (DAS28 or SDAI or CDAI) for all the patients, in par-
ticular those included in the SCQM registry. These baseline
US data are useful not only for disease monitoring (see be-
low) but also for assessing the prognostic value of US in
comparison with other measurements of disease activity in
future registry studies. For the SONAR score, a total B-
mode score above 9 (out of 66) and more than one joint
with grade 2 synovitis or any activity on PD strongly sug-
gest the presence of active disease. When the DAS28 score
is above 5.1 (very active disease), the mean total B-mode
SONAR score is about 15 [34].
Rheumatoid arthritis monitoring
a) Good correlation between the Disease Activity Score
and ultrasound at baseline
When both baseline US scoring and a clinical index such as
DAS28 show the presence of either very active or moder-
ately active disease, we recommend the use oof nly DAS28
or another validated clinical activity index to monitor ther-
apy until remission or low disease activity is obtained.
b) Absence of correlation between the Disease Activity
Score and ultrasound at baseline
In the case of a discrepancy between baseline US score
and clinical indices, the clinician should re-evaluate the
diagnosis. If RA is confirmed, we feel that the use of US
should be preferred for treatment monitoring because it has
been shown to be more reliable than clinical indices. Dur-
ing follow-up, the minimal clinically relevant change in
total B-mode score should be above 3.5, and appearance or
disappearance of grade 2 synovitis must be especially eval-
uated [34]. Change in Doppler activity should be preferred
to B-mode changes prior to any treatment modification [3].
c) Good correlation between the Disease Activity Score
and ultrasound when treatment goals are achieved
We recommend that US scoring is performed when treat-
ment goals are achieved and remain sustained for at least
6 months, prior to considering treatment tapering. When
signs of active synovitis on US (no Doppler activity or
and less than 2 grade 2 synovitis on B-mode) [3] have dis-
appeared, treatment tapering should be considered, since
many studies have shown that this was possible with both
traditional and biological disease-modifying antirheumatic
drugs (DMARDs).
d) Absence of correlation between the Disease Activity
Score and ultrasound when treatment goals are achieved
If signs of active synovitis are still present on US examin-
ation the clinician should be very cautious about stepping
down therapy but instead evaluate reinforcement or change
in therapy. The US examiner must pay special attention to
the PD evaluation, in particular the absence of any residual
PD activity [41].
e) Erosion and cartilage scores
As the SONAR erosion score has not been validated, we
cannot recommend its use routinely. Nevertheless the pos-
sibility exists for the clinicians to include this information
in the SCQM database for future studies. The same is true
for the assessment of cartilage lesions in particular loss of
thickness.
Recommended time intervals
a) When tailoring therapy according to US (absence of cor-
relation between US and clinical scores) intervals between
two US examinations should be at least 3 months.
However, changes in PD in response to therapy are more
rapid than B-mode changes and can occur within a few
days [7, 37].
b) When there is a good correlation with the clinical disease
activity indices after reaching the treatment goals and in the
absence of any symptomatic changes, we recommend re-
peating US evaluations once a year.
Conclusion
The best scoring system for US in the diagnosis and mon-
itoring of RA has to be defined and validated in additional
prospective studies, including randomised controlled trials
and patient registries. Currently, studies are underway to
assess the contribution of US to tight disease control and
clinical outcome. Although the results of some prospective
trials are still pending, a high level of expertise in US ex-
amination has been established in Switzerland, with many
training sessions and more than 100 participating rheum-
atologists. Thus, there is a rationale for including US as-
sessment in the daily clinical practice of rheumatologists in
charge of RA patients.
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